Dr Harry Destecroix
CEO, Unit DX
Harry is a driven entrepreneur, CEO and angel investor. He founded his first venture, Ziylo, in 2014 while finishing his PhD. In 2018 Ziylo was sold to pharmaceutical giant Novo Nordisk to aid development of a ‘smart insulin’ for diabetics. The deal was globally recognised as one of the top exits of the year. In 2017 he opened his biotech incubator Unit DX in Bristol to encourage other scientists to make the entrepreneurial leap. In two years, Unit DX is 100% full, home to 37 companies employing over 120 people. Plans for a second incubator are underway.